Podcasts about part d

Le journal de l'ASSE FB Saint Etienne

Play Episode Listen Later Jan 30, 2026 19:47

The Friday Five for January 30, 2026 Meta Announces Premium Subscriptions TikTok USDS Troubles & New Competitors FY 2026 Appropriations Bills 2025 Tax Season & H.R. 7006 CMS 2027 MA and Part D Advance Notice Get Connected:

Départ d'Eirik Horneland : un échec à tous les niveaux de l'ASSE

Play Episode Listen Later Jan 29, 2026 2:57

durée : 00:02:57 - 100% Sainté, la chronique Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

radio france chec part d niveaux

1270. Fr Joe's Faith Restart part d | January 28, 2026

Joe In Black Ministries Podcast

Play Episode Listen Later Jan 28, 2026 60:30

Send us a textFr Joe dives into the content of January video postings on Social Media: #FaithRestart2026Check out the JIBM Web site at: https://www.joeinblackministries.com/Please use the following link if you would like to financially support Church of the Holy Family: https://pushpay.com/g/hfgrandblanc?sr…Support the show

church restart holy family part d fr joe

Fundamental Doctrine Of Jesus Christ. Part D

doctrine fundamental part d jesus christ part

Play Episode Listen Later Jan 28, 2026 29:15

Fundamental Doctrine Of Jesus Christ. Part D

Départ d'Eirik Horneland de l'ASSE, émission spéciale de 100% Sainté

Le débrief FB Saint Etienne

Play Episode Listen Later Jan 28, 2026 20:50

durée : 00:20:50 - 100% Sainté - C'était une rumeur depuis quelques jours, cela devrait être une réalité : le départ d'Eirik Horneland de l'ASSE. Émission extraordinaire de 100% Sainté. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

mission radio france part d 100% saint c

Minnesota : départ d'agents de l'ICE

À la une

Play Episode Listen Later Jan 27, 2026 22:58

Des agents de l'ICE déployés à Minneapolis vont commencer à quitter la ville aujourd'hui.

minnesota ice minneapolis part d 'agents

Protect Your Medicare: How to Avoid Bad Switches, Spam Calls & Coverage Surprises

Money Matters with Ken Moraif

Play Episode Listen Later Jan 23, 2026 12:38

Medicare can be confusing when phone calls, mailers, and pop-up offers ramp up. In this episode, Ken Moraif and Medicare specialist Lynn Timm explain practical ways to protect yourself: how unsolicited plan “switch” calls happen, why beneficiary forms and provider networks matter, how Part D changes can affect prescriptions, and why your safest move is working with a trusted, licensed professional who knows your needs and doctors.We cover common missteps that lead to higher premiums, lost drug coverage, or out-of-network surprises and simple steps to check your current plan before you accept any offer over the phone.If this helped, tap Like and Subscribe for more retiree-friendly guidance on Medicare, Social Security, investing, and planning.00:00 – Introduction: How to Avoid Becoming a Medicare Victim01:20 – The Medicare Scam Problem: TV Ads, Phone Calls, and Confusion03:05 – Real-Life Example: How Medicare Plans Get Changed Without Consent05:10 – How Marketers Target Seniors Turning 6506:45 – Illegal & Misleading Practices: What Medicare Will Never Do08:20 – How to Protect Yourself: What to Do (and What Not to Do)10:45 – Key Takeaways + Preview of Part Two on Rising Medicare PremiumsRPOA Advisors, Inc. (d/b/a Retirement Planners of America) (“RPOA”) is an SEC-registered investment adviser. Registration as an investment adviser is not an endorsement by securities regulators and does not imply that RPOA has attained a certain level of skill or training.This podcast has been prepared for informational and educational purposes only. It is not intended to provide, and should not be relied upon for, personalized investment, financial, tax, or legal advice. RPOA does not provide tax or legal advice. You should consult your own tax and legal advisors before engaging in any transaction or strategy.Opinions expressed are those of RPOA as of the date of publication and are subject to change. Investing involves risks, including possible loss of principal. Diversification and asset allocation do not guarantee a profit, nor do they eliminate the risk of loss. Past performance is no guarantee of future results.

investing protect sec surprises illegal medicare coverage social security spam phone calls diversification switches part d avoid becoming

La Maison des Mondes Africains : "Présenter la part d'africanité de la France"

Culture en direct

Play Episode Listen Later Jan 14, 2026 9:54

durée : 00:09:54 - Le Point culture - par : Marie Sorbier - Lieu culturel voulu par Emmanuel Macron, la MansA, la Maison des Mondes Africains a ouvert ses portes en octobre dernier à Paris avec l'ambition de propager la parole afro-descendante, plus de soixante ans après les indépendances. - réalisation : Laurence Malonda - invités : Liz Gomis Directrice de la Maison des Mondes Africains

emmanuel macron la france la maison le point mondes senter part d la part africains laurence malonda

Episode 332: Cornerfest ‘26 Part D

Chilluminati Podcast

Play Episode Listen Later Jan 11, 2026 139:44

Cornerfest is back, baby! Join Mathas and Jesse as Alex takes them on a journey through the corners of the internet in this final part of the yearly series.CHILLUMINATI is a weekly comedy podcast hosted by Mike Martin, Jesse Cox and Alex Faciane. Hold on to your tin-foil hats and traverse the realms of the mysterious, supernatural, spooky and sometimes truly horrible - and your third eye will never be the same!Subscribe to our Patreon to support us and for extra content like full video episodes, weekly Minisodes, exclusive art, and more at http://patreon.com/CHILLUMINATIPODThank you to our sponsors:Mike Martin - http://www.youtube.com/@themoleculemindset Jesse Cox - http://www.youtube.com/jessecox Alex Faciane - https://www.youtube.com/@StarWarsOldCanonBookClub/Thanks to Factor: head to https://www.factormeals.com/chill50off!Editor: DeanCutty Producer: Hilde @ https://bsky.app/profile/heksen.bsky.social Show Art: Studio Melectro @ http://www.instagram.com/studio_melectro Logo Design: Shawn JPB @ https://twitter.com/JetpackBragginSHOWNOTESMAN OF WIND:https://www.instagram.com/jesusthelivingsun?igsh=ZDc3dGtjZmtrZDVs https://www.amazon.com/dp/B0FMFYF8YQ?ref_=quick_view_ref_tag https://www.youtube.com/watch?v=W7_F_AqeRqoTHE DEATH OF DR. KELLY:https://en.wikipedia.org/wiki/David_Kelly_(weapons_expert) https://www.theguardian.com/politics/2013/jul/16/david-kelly-death-10-years-on https://www.bbc.com/news/uk-13716127 https://www.spyculture.com/clandestime-146-the-death-of-david-kelly/ https://www.theguardian.com/politics/2010/jan/25/david-kelly-suicide-hutton-inquiryhttps://www.theguardian.com/theguardian/2004/jan/27/guardianletters4EVEN DEADER INTERNET:https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5085878 https://gizmodo.com/dead-internet-theory-lives-one-out-of-three-of-you-is-a-bot-2000656924https://radar.cloudflare.com/traffic?dateRange=52w#bot-vs-humanhttps://www.theatlantic.com/technology/archive/2021/08/dead-internet-theory-wrong-but-feels-true/619937/https://forum.agoraroad.com/index.php?threads/dead-internet-theory-most-of-the-internet-is-fake.3011/https://www.youtube.com/watch?v=02Ah5VQrzvADATURA STRAMONIUMhttps://www.reddit.com/r/spookymysteries/comments/n16xl8/solvedish_clairvius_narcisse_a_real_life_zombie/ https://en.wikipedia.org/wiki/The_Serpent_and_the_Rainbow_(book) https://www.biologyonline.com/articles/dead-man-walkinghttps://web.archive.org/web/20210228034502/http://isciencemag.co.uk/features/haitian-zombies/https://www.youtube.com/watch?v=LNRnOcW5yqsPALANTIR REDDIT HEISThttps://www.reddit.com/r/SubredditDrama/s/mKUmT9YlR0

factor rainbow serpent part d mike martin david kelly minisodes jesse cox alex faciane chilluminati

Ringing in the New Year with CMS

Journal of Clinical Oncology (JCO) Podcast

Play Episode Listen Later Jan 9, 2026 16:51

The Friday Five for January 9, 2026: Rural Health Transformation Program Allocations Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model Global Benchmark for Efficient Drug Pricing (GLOBE) Model Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model Clear, Accurate, and Actionable Health Care Prices Get Connected:

new year tiktok social americans office government lifestyle nutrition awards states billion transparency threads medicare coverage centers gov medicaid accurate actionable glp cms ritter ringing medicaid services part d usable friday five fmo expand access fierce healthcare

Association Between EOL SACT and Healthcare Utilization

Play Episode Listen Later Jan 8, 2026 23:00

Host Dr. Davide Soldato and guests Dr. Kerin Adelson and Dr. Maureen Canavan discuss JCO article "Association Between Systemic Anticancer Therapy Administration Near the End of Life with Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality," highlighting adverse outcomes for patients who receive any type of systemic anticancer therapy(SACT) at EOL (end of life) and the need for better communication between oncologists and patients regarding expected risk and benefits of such treatments to properly align goals-of-care. TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO authors Dr. Maureen Canavan, epidemiologist and associate research scientist at Yale Cancer Outcomes, Public Policy and Effectiveness Research Center; and by Dr. Kerin Adelson, Chief Quality and Value Officer, medical oncologist, and clinical researcher on health services and clinical care delivery at MD Anderson Cancer Center. In the manuscript "Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER-Medicare Analysis of End-of-Life Care Quality." that you recently published in the JCO, you performed an analysis that included more than 30,000 older adults in the SEER-Medicare database, and you observed that 7.6% of these patients received any systemic anticancer medication within 30 days of death. So, I wanted you to explain why you thought that this was a priority right now, and whether there was any previous data that was published in the literature, and if you think that there was any significant gap in the literature that led you to the research you just published. Dr. Kerin Adelson: We have published a series of articles looking at real-world trends in patterns of care, particularly related to systemic anticancer therapy at the end of life. This has been gaining increasing focus in recent years because of the understanding that when patients stay on systemic anticancer therapy, that is often a surrogate for a lack of goal-concordant care. So, patients who continue to receive systemic therapy have worse quality of life, are more likely generally to have a medicalized death, and less likely to use hospice. And what our prior work has shown is that more and more we are seeing patients using immunotherapies and targeted therapies towards the end of life. No prior work had really comprehensively examined whether these novel therapies were associated with those same patterns of care increases in acute care utilization and decreases in hospice. Dr. Davide Soldato: So basically, the data that we had up until that point was mostly with cytotoxic chemotherapy, and the emergence of this new treatment, which frequently are thought to be less toxic and so less problematic also in the end of life, led to this research. Is that correct? Dr. Kerin Adelson: Correct. Dr. Maureen Canavan: I would also build on that. I think that as the landscape of cancer care changes, it is important to really understand the availability of treatments, but then also, as Kerin noted, it is important to focus on goal-concordant care. We have established literature, studies we have done and some other studies that have looked at cytotoxic chemotherapy, but with the emergence of these targeted therapies, we really did not know a few things. We did not know the rates of utilization in a large national population, and how that was associated with these elements of medicalized death like ED use, hospitalizations, acute care use. So this was really a question that we had going into it. How can we expand the knowledge base so that both patients and providers can be more cognizant when thinking about goals of care conversations and ensuring that that is in place? Dr. Kerin Adelson: And our work has kind of evolved to answer some critical questions. So, one of our early papers looked at different rates of systemic anticancer therapy at the end of life, and that is where we showed that we were seeing a lot more immunotherapy and targeted therapy. And then we asked the question, well, oncologists generally when they give these treatments, they are hoping that those treatments are going to work and help the patients live longer. So we did another paper where we actually looked at practices who were more aggressive near the end of life and whether they had better overall survival than practices that were less aggressive, accounting for the fact that there could be populations of patients who benefited. And in fact, we showed there was no survival difference. So then this paper sort of answered the question: Well, if it is not having benefit, is this treatment actually doing harm? And this study gets at that question: What are the harms of continuing patients on therapy past the point of benefit? Dr. Maureen Canavan: And I think building off of that, the use of the SEER-Medicare database is a quite robust database. So in this, we have very specific data we can track. We can track the exact type of treatment they had, you know, was it a targeted therapy? Was it immunotherapy? So looking at those subclasses of therapy. We were also able to directly link it within that time frame to the acute care utilization, a limitation that we had in some of our previous work that that data was not always available. So it is more focused in the sense that we were looking at older adults, so patients 66 years of age and older, but we were able to get those individual metrics. So to Kerin's point, we did not see the survival benefit. What do we see then for these medicalized death elements? So the higher rates of all of them across the board. Dr. Davide Soldato: So coming back to the cohort and to the data that you utilized, Dr. Canavan mentioned the use of the SEER system to analyze these data. You already mentioned that you included mostly older adults, so those aged 66 and more. And also there was a little bit of restriction regarding the fact that the patient needed to be covered by Medicare in the last year of death concerning Part A and Part B, and the last 30 days from death concerning Part D. So I just wanted to ask a little bit of a question regarding these findings and whether you think that we also need additional work, especially in the younger population because I think it is something that all of us who work in oncology have seen. The aggressiveness, and this is also something that you showed in your data, tends to increase as the age of the patient tends to decrease. So we tend to be more aggressive towards younger patients. So just a comment on that on the population and generalizability of the findings. Dr. Maureen Canavan: Yeah, I will start with the data question element. Thank you. I think there are a few things to point out for that. So in terms of the restriction to ensure that they had continuous Part D coverage, that was necessary for us to track their oral medication use during that time. So kind of an easy response. The Part A, Part B requirement, it is actually pretty widely used in studies of SEER-Medicare data, and that is you want to establish the patient population, that they are not getting treated with another insurance provider in some way that you are not able to track. So that ensures that we can track not only their systemic anticancer therapy use but also when we are trying to make sure that we are controlling for confounders like chronic conditions and stuff, we are able to track the presence of chronic conditions. So we wanted to make sure we were not biasing the data, so I think that was an important consideration. You do point out very wisely that there are then limitations with the generalizability, and I think we would be lacking if we did not account for that. But I think it is important to establish this baseline relationship association, and then you can step out, we will say, to more diverse populations. So I think we could potentially maybe try to relax the timeline to see if people that might have influx in and out of the Medicare system are still seeing those same rates. I think it is likely they would. But I think to the bigger point that you bring up is that establishing this within the older adults where, you know, we do see as they get older maybe less rates of systemic therapy, extending it to the younger population. There is a challenge with that in that just that data is not available to the robust level that SEER-Medicare is. Both Kerin and I have noted that there is the possibility to look within one specific insurance provider type. Again, recognizing the limitations of the generalizability, but always slowly pushing the needle, finding out more about younger adult populations. And I think this is maybe in an ideal world, but setting the precedent that we really do need to track this on a national scale within younger adults because they do have the need. We do see these higher rates of utilization, and really making sure again with the mindset always of the best interest of patients and the most informative to providers in how we are looking at care. So I think generalizability is definitely a goal. However, there are limitations of the availability of data for younger populations and I think that they are a necessary restraint that all researchers should acknowledge. Dr. Kerin Adelson: Yeah, I think it is important for our audience to understand that health services research and large database research is really limited by what databases are available and what are the characteristics of those databases. So we have done a lot of work in an electronic health record database, and there you can get certain kinds of granularity that you may not be able to get in a payer or a claims-based database. But what you do not get is that comprehensive look at, say, what happens if a patient goes to another practice. Claims-based databases offer you that, but research on US populations is limited by our payment system. So when you look at younger patients, there are so many different insurance companies that when you are trying to get that comprehensive view, it can be hard or very expensive actually. These commercial insurers will sell their data to different databases. So for us, the largest single payer in the United States is the US government, and that is for patients who are over age 65, and that is why you see lots of US-based studies done in the Medicare population. Interestingly, a recent paper by a Canadian group showed very, very similar patterns. It was a significantly smaller study but, right, Canada is a single-payer system and so they were able to really look at all ages, and we did see the same patterns of care in a different payment system. Dr. Davide Soldato: Going back a little bit to the type of treatments that were observed in your manuscript, so we start from a 7.6% of patients who received any type of systemic anticancer therapy within 30 days from death. And when we split the different categories that you analyzed, which I think is a very strong aspect of your manuscript, we see that more or less 50% of the patients received chemotherapy, 20% more or less received immunotherapy, more or less 20% targeted therapy, and then there is a combination of those agents. So just wanted to have a little bit of your opinion compared also to the data that you already published and that you mentioned before. Was this in line with previous data? Was there anything surprising about this? We saw a little bit of a raise in the use of immunotherapy and targeted therapy as you were saying, but still, there is a very high proportion of chemotherapy, 50%. Dr. Kerin Adelson: So I think that really, really reflects the time period in which we studied where immunotherapies were gaining ground. There was tons of excitement and we were seeing this shift. I bet if we do the same study in five years that chemotherapy percent may even go down to half, and we are going to see more and more targeted and immunotherapies, and that is just reflecting the pattern of drug discovery that we are seeing. Dr. Davide Soldato: Coming to the real question that you wanted to answer with this manuscript, so is systemic anticancer therapy associated with worse outcomes in terms of healthcare utilization and use of hospice resources? Was there any hint that for example immunotherapy was related to less of these adverse outcomes? Dr. Kerin Adelson: So I will be honest, I was a little bit surprised that the combination of chemotherapy and immunotherapy was that much more strongly correlated with acute care use at the end of life. You know, I had really thought most likely that what we would see were similar rates. And we did. Each different type of systemic anticancer therapy was associated with significantly higher odds of ending up in the hospital, going to the ICU, dying in the hospital, going to the ED. But that group that got dual therapy was that much higher, you know, over three times the risk. And that surprised me because what it suggested is that there is likely a component of treatment toxicity that is leading to some of the acute care use. It is not simply just a constellation of patients who have not yet transitioned towards hospice or palliative care or end-of-life care who are then more likely to end up in the hospital. But the fact that we see a difference between, say, single-agent immunotherapy and dual combination with chemotherapy does suggest that the treatments are actually contributing to some of what we are seeing. Dr. Davide Soldato: But still, all of the treatments that you evaluated were still associated with higher healthcare utilization. Like there was no signal that, for example, giving immunotherapy at the end of life was not associated with these adverse outcomes. Correct? Dr. Kerin Adelson: Correct. And you will find oncologists out there who will say, actually, these treatments are so good that they might actually lower rates of hospitalization because they keep patients healthy. And certainly, that may be true upstream or earlier in the course of disease, but at the end of life, any form of systemic anticancer therapy is really a surrogate marker for lack of transition towards what is likely appropriate end-of-life therapy. And I just want to point out that time spent in the hospital, going back and forth to invasive procedures, going to the intensive care unit, even going back and forth to an infusion center, that is time that is not spent at home with loved ones for people who have very little time left to live. Dr. Davide Soldato: Thank you very much. That was exactly the point that I wanted you to stress because I think it is really the most important message that we can get as oncologists from this manuscript. Like there is no treatment that is not associated with potentially harming our patient and, as you were saying, taking off time with loved ones in a critical period of the life of these individuals who have been diagnosed and treated for cancer. So, basically what we saw in the paper was a 7.65% utilization of systemic anticancer therapy. And I might imagine that for some oncologists or for some hematologists that might not actually be that much. Like they could potentially say, "Okay, but it is like 7%, it is not that high. I would have expected something higher." So I just wanted a little bit of perspective regarding also quality metrics that we have available for these types of indicators at end-of-life care. What would be the appropriate percentage of people receiving any type of treatment within 30 days from death? Dr. Maureen Canavan: A couple caveats, as a data person I always like to give those. This was among all cancer patients, so not necessarily patients that had been on active treatment. So I think that number was actually quite lower than when we looked in another study about patients that had chemo within the last year, so on, you know, active treatment. So I think that is an element to take into consideration is that those numbers will vary based on who your denominator population is. So that is important to consider. Additionally, the National Quality Forum, they call for reducing rates of systemic therapy at end of life. But I think they, similar to how I would be, are cautious to point out this is the exact number, or it should be zero. Because there are cases where you have to go in line with patient preferences. And if a patient is very adamant that they want to continue treatment, that needs to be a decision that comes between them and their provider. So, you know, the zero, though sounding ideal to us who want to encourage transitions and encourage goals of care conversation is a nice number, it is not a realistic. So, to evade your question completely, I do not think there is a set number. But the goal is to make sure that both patients, providers, everyone is informed and is making the best holistic decision. So there is this natural tendency, I think, to keep fighting both for the patient and the provider to try to beat something, but recognizing the point at which we are beyond a benefit of treatment and what would be most beneficial to the patient in terms of getting back to that idea of, you know, the time with their families and whatnot. So is the number zero? No. Could it probably be lower than we have? I think yes, definitely. Dr. Kerin Adelson: I completely agree with everything Dr. Canavan said. I think one of the other challenges is that this data isn't being tracked and publicly reported across the world. And so what that optimal rate is, is a little unclear. We see different rates also depending on the population included. So one of the things Dr. Canavan said is our database included patients who were likely treated long ago for cancer and cured of their cancer. So they were less likely to die on systemic therapy. But until everybody starts tracking and reporting, it is really hard to know where we are as a country or really as a global population, and then what are the bars that we want to achieve in driving down the rates. I think some data shows that probably something in the range of 10% or below, you know, for patients who have more active cancer is probably where we should be going and driving towards. But until we have more public reporting of these metrics and consistency in how we measure them, it is really hard to come up with a single number. Dr. Davide Soldato: I have the impression that sometimes there is also a little bit of difficulty for the oncologist or the hematologist to really understand who are the patients who are approaching end of life. So there has been some data and you also report some of them in the discussion of the manuscript regarding, for example, prompts inside of the electronic health records or the use of artificial intelligence to try to predict what is the disease course. So just wanted a little bit of perspective if you think that these tools could potentially be helpful and if you think that we will be able at a certain point to implement them in routine clinical care. Dr. Kerin Adelson: I have been working on trying to do this actually at MD Anderson and coming up with a really reliable data tool that will tell us who are the patients who are going to die in short order after receiving systemic anticancer therapy. And it is not that easy, I will say. So, you know, I think we all want this amazing machine learning model that is incredibly reliable. But like any statistical test, there are problems, right? So a very sensitive test that is going to identify high, high risk of dying at the end of life is going to be compromised by false positives. And when an oncologist knows that the test might be a false positive, it becomes very hard for them to take action on it. Similarly, you know, a very, very specific test is going to be compromised by false negatives. So in that case, you could end up having patients who are at risk for dying and still treating them with chemotherapy. And so, you know, I think in the end we need some tools. It will be great if machine learning becomes very reliable and we have the right structured data elements in our electronic health records to give these reliable prediction tools. But I think there are some basic things that we all know, and those are the markers of chronicity of cancer. So patients who have had multiple lines of therapy already, right? Past the point of clinical trial benefit. Patients who have lost significant amounts of weight. Patients who are not getting out of bed and have worse performance status. Patients who are increasingly confused, right? And not mentally engaging the way they did previously. Those markers have been shown in numerous publications by a colleague of mine, David Hui and others, to really be pretty strong predictors, and they resonate with clinicians more than a machine learning score might. You know, I think when clinicians do not understand what the elements in a machine learning tool are, they are less likely to trust it and more likely to say, "Oh, it is a false positive or a false negative." But very few clinicians can argue against the fact that the patient who hasn't gotten out of bed in two weeks is somebody who is less likely to benefit. Dr. Davide Soldato: Dr. Adelson, I would like to close this podcast and I would like to thank you again for joining us today. Dr. Maureen Canavan: Thank you so much. Dr. Kerin Adelson: Thank you so much for having us. Dr. Davide Soldato: Dr. Canavan, Dr. Adelson, we appreciate you sharing more on your JCO article titled "Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER-Medicare Analysis of End-of-Life Care Quality." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can f ind all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures Kerin AdelsonStock and Other Ownership Interests: Carrum Health Consulting or Advisory Role: Abbvie, Quantum Health, Gilead SciencesPatents, Royalties, Other Intellectual Property: Genentech Other Relationship: Genentech/Roche Employment: Emilio Health/Brightline Health(An Immediate Family Member) Stock and Other Ownership Interests: Emilio Health/Brightline Health, Lyra Health (An Immediate Family Member)

united states canada canadian italy healthcare journal patients claims medicare correct public policy icu seer part b royalties genoa asco part d md anderson cancer center adelson md anderson clinical oncology eol canavan kerin jco quantum health national quality forum chief quality transcript dr healthcare utilization

Why Some Drugs Are Covered Under Part B Instead of Part D

Your Medicare Community - MedicareFAQ

Play Episode Listen Later Jan 8, 2026 4:41

Ever wonder why certain medications fall under Medicare Part B instead of Part D? In this episode, we break down the key rules that determine where drugs are covered, how those differences impact your out-of-pocket costs, and why those expenses can add up fast. Plus, we explain how Medicare Supplement (Medigap) plans can step in to help reduce or even eliminate those costs—so you can make smarter, more confident Medicare decisions.

drugs medicare covered part b part d medicare part b medicare supplement medigap

Understanding Medicare OEP: Rules, Timing, and Opportunities for Agents

The Broker Link

Play Episode Listen Later Jan 6, 2026 11:46

In this episode of The Broker Link Podcast, the focus is on the Medicare Advantage Open Enrollment Period (OEP), which runs from January 1 through March 31. Josh Slattery breaks down what OEP means for both beneficiaries and agents, emphasizing that this window allows Medicare Advantage members to make a one-time plan change if their current coverage no longer meets their needs. The discussion covers key effective dates—and clarifies important marketing and compliance guidelines. While agents cannot actively urge beneficiaries to enroll during OEP, general marketing and education remain permitted. Josh also highlights the importance of retail presence and community outreach, particularly for members experiencing buyer's remorse after AEP. He provides historical context on OEP, noting its reintroduction in 2019, and clarifies that standalone Part D plans are not included during this period. This episode equips agents with the knowledge they need to stay compliant, support their clients effectively, and identify meaningful opportunities during OEP. Learn more about partnering with The Brokerage Inc. by visiting our website, www.thebrokerageinc.com. Remember to like, share, and subscribe to our show! New episodes are available every Tuesday. Join our Community! LinkedIn: https://www.linkedin.com/company/the-brokerage-inc-/ Facebook: https://www.facebook.com/thebrokerageinc/ Instagram: https://www.instagram.com/thebrokerageinc/ YouTube: https://www.youtube.com/@TheBrokerageIncTexas Website: https://thebrokerageinc.com/

community opportunities timing medicare medicare advantage part d aep oep

Ep. 896 - The very last entry in perennially favorite segment: Your Medicare Benefits 2025!

Your Medicare Community - MedicareFAQ

Play Episode Listen Later Dec 31, 2025 37:36

MEDICARE ADVANTAGE MINUTE: PHYSICIANS SAY THAT PRIOR AUTHORIZATION STANDS IN THE WAY OF MEDICALLY NECESSARY CARE! YOUR MEDICARE BENEFITS 2025: THE FINAL ENTRY: X-RAYS We receive correspondence from "Lazy Man Steve" who is wondering what he ought to do, if anything, about his Medicare supplement and Part D drug plan as the new year approaches. We wrapped the episode with a another rousing Christmas Quiz! Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+) Visit us on: BabyBoomer.ORG Inspired by: "MEDICARE FOR THE LAZY MAN 2025; SIMPLEST & EASIEST GUIDE EVER!" "MEDICARE DRUG PLANS: A SIMPLE D-I-Y GUIDE" "MEDICARE FOR THE LAZY MAN: BARE BONES!" For sale on Amazon.com. After enjoying the books, please consider returning to leave a short customer review to help future readers. Official website: https://www.MedicareForTheLazyMan.com.

amazon benefits official medicare simplest part d christmas quiz perennially last entry

Refus d'obtempérer dans le Finistère : «On part d'un fait anodin et on en arrive à un niveau de violence considérable» souligne Thomas Bonnet

On marche sur la tÃªte

Play Episode Listen Later Dec 30, 2025 13:05

Chroniqueurs : Thomas Bonnet, journaliste politique CNewsVictor Eyraud, journaliste politique à Valeurs ActuellesJules Torres, journaliste politique au JDD Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

violence arrive visitez niveau bonnet consid part d refus finist audiomeans

Refus d'obtempérer dans le Finistère : «On part d'un fait anodin et on en arrive à un niveau de violence considérable» souligne Thomas Bonnet

Pascal Praud et vous

Play Episode Listen Later Dec 30, 2025 13:05

Chroniqueurs : Thomas Bonnet, journaliste politique CNewsVictor Eyraud, journaliste politique à Valeurs ActuellesJules Torres, journaliste politique au JDD Vous voulez réagir ? Appelez-le 01.80.20.39.21 (numéro non surtaxé) ou rendez-vous sur les réseaux sociaux d'Europe 1 pour livrer votre opinion et débattre sur grandes thématiques développées dans l'émission du jour.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

violence arrive visitez niveau bonnet consid part d refus finist audiomeans appelez

La part d'ombre du jour – Abel Boyi, chroniqueur : "Comme toutes les icônes elle a sa part d'ombre, on ne peut pas contextualiser une parole qui est raciste" - 29/12

Les Grandes Gueules

Play Episode Listen Later Dec 29, 2025 1:34

Aujourd'hui, Charles Consigny, avocat, Barbara Lefebvre, professeure d'histoire-géographie, et Abel Boyi, éducateur, débattent de l'actualité autour d'Alain Marschall et Olivier Truchot.

comme aujourd peut parole toutes ombre part d la part chroniqueurs raciste olivier truchot

The Lifetime Medicare Penalties | How People Accidentally Owe Them Forever

Play Episode Listen Later Dec 22, 2025 4:46

Did you know some Medicare penalties never go away? In this episode, we break down how Part B and Part D late enrollment penalties work, why they can follow you for life, and—most importantly—how to avoid costly mistakes that can drain your retirement savings. A must-listen if you want to protect your income and make confident Medicare decisions.

forever lifetime medicare accidentally penalties part b part d

Breaking Down CMS's Proposed 2027 Rule with Josh Slattery

The Broker Link

Play Episode Listen Later Dec 18, 2025 29:35

In this episode of The Broker Link, Gillan Boyer and Josh Slattery unpack the proposed CMS 2027 rule and what it could mean for agents, consumers, and the future of the insurance industry. The discussion highlights a clear shift toward deregulation, with several proposed changes aimed at reducing administrative burden while increasing flexibility for both agents and consumers. Key topics include updates to Special Enrollment Period (SEP) rules, allowing plan changes when providers leave a network, and the removal of the 12-hour delay between educational and marketing events. Gillan and Josh also break down proposals to shorten record retention requirements for call recordings, simplify TPMO disclaimers, and eliminate certain low-value compliance requirements. The conversation explores how these changes could give agents more time to focus on what evidence shows matters most — educating and serving clients. Additionally, the episode covers proposed updates to the Stars program and discusses the long-term impact of making IRA changes permanent, particularly regarding Part D cost structures. Overall, the proposed 2027 rule signals a meaningful shift in CMS's approach — one that industry professionals are cautiously optimistic about as it moves toward a more practical, agent-friendly regulatory environment. Learn more about partnering with The Brokerage Inc. by visiting our website, www.thebrokerageinc.com. Remember to like, share, and subscribe to our show! New episodes are available every Tuesday. Join our Community! LinkedIn: https://www.linkedin.com/company/the-brokerage-inc-/ Facebook: https://www.facebook.com/thebrokerageinc/ Instagram: https://www.instagram.com/thebrokerageinc/ YouTube: https://www.youtube.com/@TheBrokerageIncTexas Website: https://thebrokerageinc.com/

community stars breaking down proposed cms slattery part d

The Hidden Cost of Roth Conversions: Avoiding Surprise Medicare Charges

Ready For Retirement

Play Episode Listen Later Dec 14, 2025 10:24 Transcription Available

Roth conversions can save thousands in taxes, but they can also trigger Medicare IRMAA surcharges that quietly add up to more than $5,000 a year. Most retirees never see it coming, because the rules for Medicare premiums don't line up with the tax brackets everyone focuses on.In this video, James breaks down how Roth conversions interact with Medicare Part B and Part D premiums, why modified adjusted gross income matters more than taxable income, and how crossing a threshold by even one dollar can change your costs for an entire year. The case study shows how a couple could save nearly a million dollars in lifetime taxes… but lose tens of thousands to unnecessary IRMAA charges if they convert without a plan. A small adjustment (converting up to the right tier instead of the wrong bracket) boosts their long-term wealth and avoids surprise premiums.If you're planning Roth conversions before RMDs begin, evaluating a 401(k)-to-Roth strategy, or trying to minimize taxes in early retirement, understanding Medicare thresholds is essential. A smart conversion plan balances tax savings with premium costs so you don't give back what you worked so hard to save.-Advisory services are offered through Root Financial Partners, LLC, an SEC-registered investment adviser. This content is intended for informational and educational purposes only and should not be considered personalized investment, tax, or legal advice. Viewing this content does not create an advisory relationship. We do not provide tax preparation or legal services. Always consult an investment, tax or legal professional regarding your specific situation.The strategies, case studies, and examples discussed may not be suitable for everyone. They are hypothetical and for illustrative and educational purposes only. They do not reflect actual client results and are not guarantees of future performance. All investments involve risk, including the potential loss of principal.Comments reflect the views of individual users and do not necessarily represent the views of Root Financial. They are not verified, may not be accurate, and should not be considered testimonials or endorsementsParticipation in the Retirement Planning Academy or Early Retirement Academy does not create an advisory relationship with Root Financial. These programs are educational in nature and are not a substitute for personalized financial advice. Advisory services are offered only under a written agreement with Root Financial.Create Your Custom Strategy ⬇️ Get Started Here.Join the new Root Collective HERE!

surprise llc sec medicare charges roth advisory hidden cost part d rmds roth conversions medicare part b irmaa

The Secret to Successful Living. Part D

secret part d successful living

Play Episode Listen Later Dec 12, 2025 29:03

The Secret to Successful Living. Part D

12-10-25 Wed PM Pastor Tim Gammons: The Names of the Savior (Part D)

Woodland Baptist Church

Play Episode Listen Later Dec 12, 2025 29:07

Wednesday evening service preaching from the pulpit of Woodland Baptist Church – Winston Salem, NC * Please feel free to visit our website at woodlandbaptistnow.com

savior names pastor tim part d wed pm gammons

What you need to know about Medicare planning

Portfolio Intelligence

Play Episode Listen Later Dec 10, 2025 17:14

Medicare is a cornerstone of retirement planning, but its complexity can leave many retirees feeling overwhelmed. In this episode, host John Bryson, head of investment consulting, investment data analytics, and education savings at Manulife John Hancock Investments, welcomes Danielle to break down the Medicare essentials you need to know for 2026 and beyond.Danielle, author of the book 10 Costly Medicare Mistakes You Can't Afford to Make, discusses the latest expected changes to Medicare. She emphasizes the importance of early research and understanding the difference between supplemental plans, such as Medicare Advantage plans and Medicare Supplement Insurance (Medigap). She also offers strategies to help avoid higher Income-Related Monthly Adjustment Amount (IRMAA) surcharges.Here's a snippet from the conversation:1 What changes are expected to Medicare in 2026?Danielle: While we don't have some Medicare figures due to the government shutdown, we can expect Part B premiums to increase a bit. Projections suggest they could rise to $206 next year. Another major change stems from the Inflation Reduction Act of 2022, which led several carriers to exit the Part D market. As a result, about 2 million people are likely to lose their Medicare Advantage plans. If you've received a notice that your plan is exiting the market, it's important to shop for a new plan promptly to ensure you have coverage in place for January 1.2 What's IRMAA and how does it affect Medicare costs?Danielle: IRMAA is a surcharge on Medicare Part B and Part D, based on your income. While the base rate in 2025 is $185, an IRMAA surcharge will increase that amount. As a result, Part B premiums for people in really high-income brackets can increase to over $600 per month. So, decisions you make at ages 63 and 64 can affect your Medicare premiums at 65 and 66. It's wise to work with your financial advisor to plan ahead to explore spreading out income or avoiding large distributions that may help prevent higher premiums later.

medicare projections afford inflation reduction act part b medicare advantage part d medicare part b irmaa medicare planning john bryson

5 Takeaways from the CMS 2027 MA and Part D Proposed Rule

Play Episode Listen Later Dec 5, 2025 12:15

CMS recently published their 2027 Medicare Advantage and Part D Proposed Rule. In this week's Friday Five episode, we talk initial takeaways and the impact on agents and beneficiaries. Get Connected:

Episode 28: Inside the 2027 MA and Part D Proposed Rule: Star ratings, equity, and what plans must do next

RISE Radio

Play Episode Listen Later Dec 5, 2025 57:36

In this hour-long episode of RISE Radio, Editorial Director Ilene MacDonald sits down with industry experts to break down the changes in CMS' 2027 Medicare Advantage and Part D proposed rule, why removing 12 measures and bringing back the reward factor is a true Stars redesign, and how plans can pivot from operational wins to outcome performance. We also explore the new depression screening measure and the new SEP when providers exit networks, with clear steps to protect quality and retention.Our guests are Ana Handshuh, principal of CAT5 Strategies, Melissa Smith, founder and senior advisor of the Newton Smith Group, and Rex Wallace, founder & principal of Rex Wallace Consulting. For more on these changes, join us at The RISE Star Ratings Master Class, December 16-18 in Frisco, Texas or RISE National 2026, March 23-25 in Orlando, Fla.

texas stars equity cms fla frisco medicare advantage part d star ratings proposed rule melissa smith rise radio

Ep. 886 - U of AZ prostitutes self; Sells stadium name to Yaqui Indian casino magnates!

Murder Mile True-Crime Podcast

Play Episode Listen Later Dec 5, 2025 37:13

MEDICARE ADVANTAGE MINUTE: MA plan member satisfaction facing headwinds! YOUR MEDICARE BENEFITS 2025: TDAP (Tetanus, Diphtheria and Pertussis) shots Advice from Diane Omdahl: Review your drug plan in case the government plan finder "glitches". Correspondence: Peter wants to know whether he should consider changing from HDG to Plan G. This is not something I usually recommend. Fr. David takes no prescription drugs but has been paying through the nose for an expensive Part D drug plan. What should he do? Ray has more questions about how to ensure that he has the best PDP (Prescription Drug Plan) next year. Finally, we review a Gallup pole listing the states from highest to lowest for cost & availability of medical treatment. Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+) Visit us on: BabyBoomer.ORG Inspired by: "MEDICARE FOR THE LAZY MAN 2025; SIMPLEST & EASIEST GUIDE EVER!" "MEDICARE DRUG PLANS: A SIMPLE D-I-Y GUIDE" "MEDICARE FOR THE LAZY MAN: BARE BONES!" For sale on Amazon.com. After enjoying the books, please consider returning to leave a short customer review to help future readers. Official website: https://www.MedicareForTheLazyMan.com.

amazon indian official stadiums casino sells gallup prostitutes simplest part d yaqui diphtheria plang magnates

#237 - Patrick MacKay: Two Sides of a Psychopath - Part D (Leslie Frank Goodman)

Play Episode Listen Later Dec 4, 2025 77:08

This is Part D of F of Patrick MacKay: Two Sides of a Psychopath, about the killing of Leslie Frank Goodman.Thursday 13th of June 1974, six months after Stephanie Britton & Christopher Martin's double murder, 64-year-old Leslie opened his shop on Rock Street in Finsbury park at just shy of 7am. At 5pm, he planned to close-up early to watch the World Cup, but was beaten to death by his last customer. But was this Patrick MacKay? He confessed to the robbery, but not the murder.This series explores the killings he confessed to, and which he committed. Location: ‘L Goodman', Rock Street (number unknown), Finsbury Park, London, UK, N14Date: Thursday 13th of June 1974 at 5pmVictims: Leslie Frank GoodmanCulprit: Patrick David MacKay? For Parts 1 to 4 covering the life of Patrick MacKay, his crimes, his trial and the three murders he was convicted of, check out Patrick MacKay: Two Sides of a Psychopath by True Crime EnthusiastFive time nominated at the True Crime Awards, Independent Podcast Awards and the British Podcast Awards, Murder Mile is one of the best UK / British true crime podcasts covering only 20 square miles of West London. It is researched, written and performed by Michael of Murder Mile UK True Crime Podcast with the main musical themes written and performed by Erik Stein and Jon Boux of Cult With No Name and additional music, as used under the Creative Commons License 4.0. A full listing of tracks used and a full transcript for each episode is listed here and a legal disclaimer.This episode features a promo by our friends at the Three Ravens podcast. For links click hereTo subscribe via Patreon, click here Support this show http://supporter.acast.com/murdermile. Hosted on Acast. See acast.com/privacy for more information.

uk world cup acast goodman psychopaths two sides mackay west london part d british podcast awards christopher martin finsbury park finsbury murder mile three ravens cult with no name

The Power Of The Resurrection. Part D

Your Finances Untangled with Moise Piram

Play Episode Listen Later Dec 3, 2025 31:19

The Power Of The Resurrection. Part D

resurrection part d

The Hidden Cost of Having Multiple Advisors

Play Episode Listen Later Nov 20, 2025 35:40

STOP Using Multiple Financial Advisors Before You Watch This!Are multiple financial advisors helping or quietly hurting your planIn today's episode Andrew Nida and Moise Piram from Asset Management Group Inc unpack the hidden costs of splitting assets across advisors including surprise capital gains IRMAA surcharges missed Roth conversion windows wash sales and fee creepWe walk through a real case where an $86,000 capital gain from an uncoordinated account triggered higher Medicare premiums derailed tax planning and cost tens of thousands in avoidable dragWhat you will learn• Why diversifying investments is smart but diversifying advisors fragments your strategy• How IRMAA surcharges and the two year lookback can compound one decision• The coordination gap that kills Roth conversions tax loss harvesting and withdrawal sequencing• A simple audit to decide whether consolidation makes sense for youIf you find this helpful like share and subscribe to stay current on financial planning tax planning wealth management and moreFollow us onX.com: https://x.com/AMGinc_ATLInstagram: https://www.instagram.com/assetmanagementgroupinc/LinkedIn: https://www.linkedin.com/company/amgincatl/Facebook : https://www.facebook.com/beyondtomorrowpodcastWebsite: https://www.assetmg-inc.com/YouTube: https://www.youtube.com/@assetmanagementgroupincTikTok : https://www.tiktok.com/@assetmanagementgroupincBlog: https://www.assetmg-inc.com/blogDisclosureEducational content only. Not tax, legal, or investment advice. Tax laws can change. Consult your CPA or advisor about your specific situation.multiple financial advisors, hidden cost of multiple advisors, IRMAA surcharges, Medicare premiums, Roth conversion timing, capital gains surprise, tax planning for retirees, high net worth investors, everyday millionaires, wealth management podcast, advisor consolidation, fee analysis, wash sale rules, withdrawal sequencing, retirement income planning, Asset Management Group Inc, Andrew Nida, Moise Piram, portfolio coordination, tax efficiency, retirement tax strategies, Medicare Part B costs, Part D surcharges, financial planning mistakes, investment strategy, estate planning coordination, high income professionals, financial podcast

cpa tax medicare roth advisors consult hidden cost part d youif onx medicare part b irmaa planin

Why People Are Ahead. Part D

Play Episode Listen Later Nov 14, 2025 29:50

Why People Are Ahead. Part D

part d

Prescription Drug Pricing: MFN & GENEROUS

Play Episode Listen Later Nov 14, 2025 19:37

The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model Get Connected:

american tiktok texas donald trump apple social house media americans food government cross market cost iphone record white house congress vote bbc 3d cnn ending fight investors phase guardian millions senate npr federal wear agent delta stock vice fda naturally diabetes usa today pbs lower snap piece agriculture mart threads personally pfizer depending applications cnbc administration medicare wired generous centers ivf gov business insider number one savings medicaid thc ozempic trump administration starter astrazeneca politico airpods nbc news us government bmi glp hemp cms reopen participating aca merck ritter drug administration veterans affairs bbc news axios dtc caballero wegovy medicines us history cloth eli lilly beneficiaries novo nordisk farm bills dallas morning news cnet prescription drugs number two stiles mounjaro united states government approvals medicaid services part d desjardins yarrow more americans manisha rural development ap news appropriations number three lower costs zepbound dunleavy fraiser drug pricing number four number five issey miyake friday five mfn guardian news fmo expand access public broadcasting service trulicity dallas news cable news network brewbound state medicaid fierce healthcare united states senate committee abc7 los angeles bao bao nbcuniversal news group military construction fierce pharma

Ep. 878 - One million victims will be hit with.....disaster? NO! This is OPPORTUNITY!

amazon opportunities disasters official victims medicare one million correspondence simplest part d

Play Episode Listen Later Nov 14, 2025 32:53

Medicare Advantage Minute: United Healthcare Projects A 1,000,000 Member Drop in Medicare Advantage Enrollment Your Medicare Benefits 2025: Skilled Nursing Facility Care Correspondence with client Richard: He wondered whether he had to "re-up" (re-enroll) in his Medicare supplement and/or his Part D drug plan. Turns out he received a very scary "scam" e-mail raising concern that his insurance was about to lapse. Correspondence with soon-to-be client Kelly: She is worried about the level and quality of customer service she will have with a particular company. In my view she was misled by a government website. Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+) Visit us on: BabyBoomer.ORG Inspired by: "MEDICARE FOR THE LAZY MAN 2025; SIMPLEST & EASIEST GUIDE EVER!" "MEDICARE DRUG PLANS: A SIMPLE D-I-Y GUIDE" "MEDICARE FOR THE LAZY MAN: BARE BONES!" For sale on Amazon.com. After enjoying the books, please consider returning to leave a short customer review to help future readers. Official website: https://www.MedicareForTheLazyMan.com.

Why Am I Receiving A Part D Penalty?

Medicare Moments

Play Episode Listen Later Nov 12, 2025 7:58

On Thursday, Nov. 20, at 4 p.m. CST, Toni will host a “2026 Confused About Medicare” Zoom online nationwide workshop to explain how to enroll in Medicare the right way as well as changes for 2026 Medicare’s Part D Prescription Drug plans. Visit www.tonisays.com to register. Part D is Medicare's prescription drug plan. If you do not enroll properly, you can incur a Part D penalty that will stay with you throughout your Medicare lifetime. Toni plains how you can avois a Part D penalty. Toni's new Medicare Survival Guide Advanced Edition book is available now - pick up your copy at www.tonisays.com Download your Free Guide: How Do I Enroll in Medicare? https://tonisays.com/free-download-how-to-enroll/ Remember - with Medicare it's what you don't know that will hurt you! There's so much good information in this podcast, please be sure to share this podcast with your friends! Recognized by feedspot.com as one of the best Medicare Podcasts in the nation! Write Toni - info@tonisays.com. Toni's book is available at www.seniorresource.com and https://tonisays.com You can call Toni at 832-519-8664 Toni welcomes all Medicare questions. Toni now offers informative Medicare Webinars for all of your Medicare needs at https://tonisays.com You can find Medicare Moments wherever you find your favorite podcasts, such as: Apple: https://apple.co/44MoguG Spotify: https://open.spotify.com/show/7c82BS4hb145GiVYfnIRsoAmazon Music: https://music.amazon.com/podcasts/884c1f46-9905-4b29-a97a-1a164c97546b/medicare-moments?refMarker=null You can find Medicare Moments at: https://podcasts.seniorresource.com/medicare-moments/ Toni's new book: Maze of Medicare is now available at www.tonisays.com Combining Scripture with Medicare, it is the only book of its kind. Toni's columns appear weekly in about 100 newspapers across America. If you would like Toni's column to appear in your local paper, or if you would like Toni to speak at an event - contact Toni King at 832-519-8664 Thank you for listening and be sure to tell your friends about Medicare Moments! Blessings! Toni KingSee omnystudio.com/listener for privacy information.

america apple zoom blessings receiving medicare recognized maze penalty part d refmarker

Ep. 874 - Increasing turmoil in the Medicare Advantage market; a plan boss explains why!